Today we revealed a bold ambition to deliver $80bn in total revenue by 2030 ($45bn in 2023). We are set to launch 20 new medicines by 2030 as we bring patients next generation therapies. We will also halve emissions across our value chain by 2030. #AZN #WhatScienceCanDo

Cardiovascular diseases such as heart failure often coexist with renal disorders such as chronic kidney disease. These diseases share common risk drivers including hypertension and dyslipidaemia. Learn about managing care for these interconnected diseases: learn.az/6014jW9O2

COPD is a complex disease that can impact both the lungs and heart – termed cardiopulmonary risk. Through scientific innovation and partnership with the medical community, we’re advancing a more proactive approach to address the varied risks elevated by COPD. Learn more. #ATS2024

Respiratory diseases like asthma and COPD are complex, with patients still having unmet needs. As leaders in respiratory care, we seek more than symptom control. Join us at #ATS2024 as we follow the science to transform care today and for the future. learn.az/6012dRys8

Our Young Health Programme is working to deliver better health choices for brighter life chances. Empowering young people to avoid risk factors can help prevent diseases that can occur later in life. Learn more: learn.az/6015dXQk1 #WorldHypertensionDay #YoungHealthProgramme